CYTK

Cytokinetics, Incorporated

Healthcare · $8.1B market cap

We can't put a fair value on CYTK right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-6.0% a year✗

Equity per share growth-15.7% a year✗

Sales growth5.9% a year✗

Free cash flow growth24.0% a year✓

Return on invested capital-52.3%✗

Follow CYTK

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

None of the investors we track holds CYTK right now. In Q1 2026, 1 sold out. Who we track

Moves in Q1 2026

Sold out: Polen Capital Management

Insider activity

Since Sep 8, 2026: no open-market purchases, 2 sales worth $339K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Sales

Landry Robert E

director · 2026-09-11

Sold

$75K

Malik Fady Ibraham

EVP Research & Development · 2026-09-08

Sold

$264K

Other filings

Malik Fady Ibraham

EVP Research & Development · 2026-09-08

Option exercise

$27K

About Cytokinetics, Incorporated

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule…

Biotechnology